Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19012978 | VIRAL VECTOR DELIVERY SYSTEM FOR BOTH RESPIRATORY AND DIGESTIVE TRACTS OF PIGS AND APPLICATION THEREOF | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18792611 | COXSACKIEVIRUS B4 STRAIN AND APPLICATION THEREOF | August 2024 | May 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18660609 | PORCINE EPIDEMIC DIARRHEA VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROM | May 2024 | February 2025 | Allow | 9 | 0 | 0 | Yes | No |
| 18644438 | ANTIBIOTIC FREE TREATMENT OF MASTITIS | April 2024 | December 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18622330 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | March 2024 | June 2025 | Allow | 14 | 1 | 0 | No | No |
| 18614158 | PROTOPARVOVIRUS COMPOSITIONS COMPRISING A PROTOPARVOVIRUS VARIANT VP1 CAPSID POLYPEPTIDE AND RELATED METHODS | March 2024 | March 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18443262 | METHOD FOR THE DETECTION AND QUANTIFICATION OF ADENO-ASSOCIATED VIRUSES (AAVs) USING AN AFFINITY MATRIX | February 2024 | January 2025 | Allow | 11 | 2 | 0 | No | No |
| 18430151 | METHODS OF IMMUNOTHERAPY | February 2024 | December 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18418127 | RSV RNA VACCINES | January 2024 | June 2025 | Allow | 17 | 1 | 0 | No | No |
| 18396787 | Porcine Circovirus Type 3 (PCV3) Vaccines, and Production and Uses Thereof | December 2023 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18394486 | RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE | December 2023 | December 2024 | Allow | 12 | 0 | 0 | No | No |
| 18542330 | RECOMBINANT HERPESVIRUS OF TURKEY VECTORS EXPRESSING ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF | December 2023 | June 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18530421 | FORMULATIONS OF DENGUE VIRUS VACCINE COMPOSITIONS | December 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18516237 | PCV2 ORF2 PROTEIN VARIANT AND VIRUS LIKE PARTICLES COMPOSED THEREOF | November 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18511123 | FOOT-AND-MOUTH DISEASE VACCINE | November 2023 | December 2024 | Allow | 13 | 1 | 0 | No | No |
| 18498879 | METHOD FOR LARGE-SCALE PRODUCTION OF LENTIVIRUS BY USING GMP-LEVEL SERUM-FREE SUSPENSION CELLS | October 2023 | August 2024 | Allow | 10 | 1 | 0 | No | No |
| 18492535 | ONCOLYTIC VIRUS IMPROVED IN SAFETY AND ANTICANCER EFFECT | October 2023 | October 2024 | Allow | 12 | 1 | 1 | No | No |
| 18287248 | LIQUID SIX COMBINED VACCINE COMPOSITION | October 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18376177 | Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18476042 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | September 2023 | August 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18242627 | HORN FLY VACCINE COMPOSITIONS AND METHODS OF MAKING SAME | September 2023 | February 2025 | Allow | 18 | 2 | 1 | Yes | No |
| 18461369 | PORCINE CIRCOVIRUS TYPE 3 IMMUNOGENIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | September 2023 | February 2025 | Allow | 17 | 2 | 0 | No | No |
| 18366839 | VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINE | August 2023 | March 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18354172 | ADENOVIRUSES AND METHODS FOR USING ADENOVIRUSES | July 2023 | July 2024 | Allow | 12 | 1 | 1 | No | No |
| 18216531 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | June 2023 | October 2024 | Allow | 15 | 1 | 1 | No | No |
| 18331083 | VIRUS-LIKE PARTICLES AND METHODS OF USE | June 2023 | July 2024 | Allow | 14 | 2 | 0 | No | No |
| 18146995 | BUNYAVIRALES VACCINE | December 2022 | April 2025 | Allow | 28 | 1 | 2 | No | No |
| 18085478 | VACCINES FOR IN VIVO EXPRESSION OF NUCLEIC ACIDS AND METHODS OF USING THE SAME | December 2022 | June 2025 | Allow | 30 | 1 | 0 | No | No |
| 17813178 | VECTORS FOR ELICITING IMMUNE RESPONSES TO NON-DOMINANT EPITOPES IN THE HEMAGGLUTININ (HA) PROTEIN | July 2022 | July 2024 | Allow | 24 | 1 | 0 | No | No |
| 17735010 | METHODS FOR LOWERING THE INFECTION RATE OF VIRUSES | May 2022 | April 2025 | Abandon | 35 | 5 | 1 | Yes | No |
| 17707613 | METHODS OF PRODUCING AND CHARACTERIZING VIRUS VACCINE AND VIRUS VACCINE COMPOSITION | March 2022 | January 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17579447 | Chimeric Papilloma Virus L1 Protein | January 2022 | June 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17618625 | PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE VIRUS | December 2021 | September 2024 | Allow | 33 | 0 | 0 | No | No |
| 17544518 | VIRAL NANOPARTICLE MULTIMERS | December 2021 | March 2025 | Allow | 39 | 2 | 0 | No | No |
| 17485857 | Paramyxovirus and uses thereof | September 2021 | March 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17469313 | COMPOSITIONS COMPRISING A NOROVIRUS NUCLEIC ACID AND METHODS OF USE THEREOF | September 2021 | August 2024 | Allow | 35 | 2 | 0 | No | No |
| 17436791 | NOVEL CORONAVIRUS ANTIBODY DETECTION KIT BASED ON MAGNETIC PARTICLE CHEMILUMINESCENCE | September 2021 | April 2025 | Allow | 43 | 1 | 0 | No | No |
| 17468419 | IMMUNOASSAY FOR SARS-CoV-2 ANTIBODIES | September 2021 | April 2025 | Allow | 43 | 1 | 1 | No | No |
| 17431987 | ROTAVIRUS VP7 FUSION PROTEINS AND ROTAVIRUS-LIKE PARTICLES COMPRISING THEM | August 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17395242 | METHOD FOR THE RAPID DIAGNOSIS OF COVID-19 USING A MOBILE GENETIC TESTING LABORATORY | August 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17428967 | IMMUNOASSAY FOR SARS-CoV-2 ANTIBODIES | August 2021 | October 2024 | Allow | 39 | 2 | 0 | No | No |
| 17421278 | PLANT COLONIZATION ASSAYS USING NATURAL MICROBIAL BARCODES | July 2021 | June 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17420442 | COMPOSITIONS AND METHODS FOR DETECTING HUMAN PAPILLOMAVIRUS | July 2021 | November 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17418131 | PHARMACEUTICAL PREPARATION FOR TREATING HEPATITIS B, PREPARATION METHOD THEREFOR AND USE THEREOF | June 2021 | January 2025 | Allow | 43 | 1 | 0 | No | No |
| 17351363 | IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | June 2021 | October 2024 | Allow | 40 | 1 | 0 | No | No |
| 17414187 | Prime-Boost Vaccination Regimen | June 2021 | July 2024 | Allow | 37 | 1 | 0 | No | No |
| 16978919 | ANTI-PD-1 VACCINE COMPOSITION | June 2021 | December 2024 | Abandon | 52 | 0 | 1 | No | No |
| 17312235 | VACCINE FOR PREVENTING OR TREATING CONGENITAL INFECTION WITH CYTOMEGALOVIRUS | June 2021 | February 2025 | Allow | 45 | 4 | 0 | Yes | No |
| 17341928 | CORONAVIRUS VACCINE AND METHODS OF USE THEREOF | June 2021 | May 2025 | Allow | 47 | 2 | 1 | No | No |
| 17299852 | HIV VACCINE IMMUNOGENS | June 2021 | October 2024 | Allow | 41 | 1 | 1 | No | No |
| 17289850 | TOOLS FOR DETECTING COCOA SWOLLEN SHOOT VIRUS COAT PROTEIN ANTIGEN | April 2021 | August 2024 | Allow | 40 | 1 | 0 | No | No |
| 17288208 | VSG-BASED VACCINATION AND ANTIBODY GENERATION PLATFORM FOR THE TREATMENT OF DISEASES | April 2021 | December 2024 | Allow | 43 | 1 | 1 | No | No |
| 17236099 | THERAPEUTIC MITIGATION OF EPITHELIAL INFECTION | April 2021 | December 2024 | Allow | 44 | 2 | 0 | No | No |
| 17285045 | VIRUS VACCINE | April 2021 | May 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17216619 | IMMUNE COMPOSITION CONTAINING gE-BASED FUSION PROTEIN OR NUCLEIC ACID MOLECULE ENCODING THE SAME | March 2021 | January 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17210252 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE BROAD-SPECTRUM HUMAN PAPILLOMAVIRUS FORMULATIONS | March 2021 | April 2025 | Abandon | 49 | 4 | 0 | No | No |
| 17273258 | DNA PLASMID-LAUNCHED LIVE-ATTENUATED VACCINES FOR PLUS-SENSE SINGLE STRANDED RNA | March 2021 | March 2025 | Allow | 48 | 3 | 1 | No | No |
| 17177724 | Novel Vaccine Compositions for Porcine Epidemic Diarrhea Virus and Porcine Deltacoronavirus | February 2021 | October 2024 | Allow | 44 | 1 | 0 | No | No |
| 17268403 | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND USES THEREOF FOR THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS DISEASE | February 2021 | April 2025 | Allow | 50 | 2 | 1 | No | No |
| 16540326 | METHOD FOR PREPARING WHOLE BOVINE-DERIVED BROADLY NEUTRALIZING ANTIBODY AGAINST SEROTYPE O FOOT-AND-MOUTH DISEASE VIRUS | August 2019 | June 2020 | Allow | 10 | 1 | 0 | No | No |
| 16240222 | LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE | January 2019 | October 2019 | Allow | 9 | 1 | 0 | No | No |
| 15779106 | VACCINE ANTIGEN WITH INCREASED IMMUNOGENICITY | May 2018 | December 2018 | Allow | 6 | 2 | 0 | No | No |
| 15768356 | PORCINE CIRCOVIRUS TYPE 3 IMMUNOGENIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | April 2018 | June 2019 | Allow | 14 | 1 | 0 | Yes | No |
| 15850696 | LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE | December 2017 | October 2018 | Allow | 10 | 1 | 0 | No | No |
| 15836083 | Immortalized Porcine Alveolar Macrophage | December 2017 | August 2018 | Allow | 9 | 1 | 0 | No | No |
| 15796403 | HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF | October 2017 | October 2018 | Allow | 12 | 1 | 0 | No | No |
| 15722180 | IMPLANTS AND METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE | October 2017 | October 2018 | Allow | 13 | 1 | 0 | No | No |
| 15703640 | ADAPTATION OF ATTENUATED INFECTIOUS BRONCHITIS VIRUS (IBV) TO EMBRYONIC KIDNEY CELLS AND VACCINE THEREBY PRODUCED | September 2017 | May 2018 | Allow | 8 | 1 | 0 | No | No |
| 15686675 | THERAPEUTIC COMPOSITION OF CAMEL MILK | August 2017 | September 2018 | Abandon | 13 | 2 | 0 | Yes | No |
| 15684358 | SENECAVIRUS A ANTIGENS AND METHODS OF USE | August 2017 | January 2019 | Allow | 17 | 1 | 1 | No | No |
| 15327759 | CONSTRAINED PROTEINS AND USES THEREFOR | January 2017 | February 2019 | Allow | 24 | 1 | 1 | Yes | No |
| 15125526 | PORCINE EPIDEMIC DIARRHEA VIRUS VACCINES AND METHODS OF USE THEREOF | September 2016 | March 2018 | Allow | 18 | 1 | 1 | No | No |
| 15102971 | Immortalized Porcine Alveolar Macrophage | June 2016 | September 2017 | Allow | 15 | 1 | 0 | No | No |
| 15052713 | VACCINE COMPOSITION COMPRISING AN IMMUNOGENIC PROTEIN AND COMBINATION ADJUVANTS FOR USE IN ELICITING ANTIGEN-SPECIFIC T-CELL RESPONSES | February 2016 | August 2017 | Allow | 18 | 1 | 1 | No | No |
| 15018857 | LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE | February 2016 | September 2017 | Allow | 19 | 2 | 1 | Yes | No |
| 14691079 | IMPLANTS AND METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE | April 2015 | June 2017 | Allow | 26 | 2 | 0 | No | No |
| 14413385 | ARTERIVIRUS PROTEIN AND EXPRESSION MECHANISMS | January 2015 | December 2016 | Allow | 23 | 1 | 1 | Yes | No |
| 14478870 | NOVEL RECOMBINANT BACULOVIRUS VECTOR AND USES THEREOF | September 2014 | January 2016 | Allow | 16 | 1 | 0 | No | No |
| 14146480 | INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD AND PROGRAM | January 2014 | August 2015 | Allow | 19 | 1 | 0 | No | No |
| 14108685 | MAMMALIAN CELLS FOR PROPAGATING VIRUS | December 2013 | November 2015 | Allow | 23 | 2 | 0 | No | No |
| 14122496 | TORQUE TENO VIRUS DIAGNOSTICS | November 2013 | August 2015 | Allow | 20 | 1 | 0 | No | No |
| 14119492 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | November 2013 | December 2015 | Allow | 24 | 2 | 1 | No | No |
| 14086902 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS | November 2013 | April 2015 | Allow | 17 | 1 | 0 | No | No |
| 14035415 | LIVE ATTENUATED REPLICATION-COMPETENT ARTERIVIRUSES HAVING DECREASED DUB/DEISGYLATING ACTIVITY | September 2013 | May 2016 | Allow | 32 | 2 | 1 | Yes | No |
| 13966565 | BACILLUS ISOLATES AND METHODS OF THEIR USE TO PROTECT AGAINST PLANT PATHOGENS AND VIRUS TRANSMISSION | August 2013 | August 2015 | Allow | 33 | 2 | 0 | Yes | No |
| 13959304 | HANDHELD DIAGNOSTIC SYSTEM WITH CHIP-SCALE MICROSCOPE AND AUTOMATED IMAGE CAPTURE MECHANISM | August 2013 | January 2016 | Allow | 30 | 2 | 1 | No | No |
| 13922482 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCES | June 2013 | July 2015 | Allow | 25 | 1 | 1 | No | No |
| 13821191 | FOOT AND MOUTH DISEASE VIRUS WITH INCREASED STABILITY AND ITS USE AS VACCINE | May 2013 | May 2015 | Allow | 26 | 2 | 0 | Yes | No |
| 13886465 | Implants and methods for treating inflammation-mediated conditions of the eye | May 2013 | December 2014 | Allow | 19 | 1 | 0 | No | No |
| 13703626 | METHOD FOR ISOLATING HEPATITIS A VIRUS OR SPRING VIREMIA OF CARP VIRUS | January 2013 | September 2013 | Allow | 9 | 1 | 0 | No | No |
| 13633633 | LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE | October 2012 | September 2015 | Allow | 36 | 4 | 0 | Yes | No |
| 13501895 | ISOLATION OF A VIRUS RELATED TO CANINE PARVOVIRUS-2 FROM A RACCOON | April 2012 | January 2014 | Allow | 22 | 2 | 1 | No | No |
| 13396444 | PREVENTION AND REMEDIATION OF PETROLEUM RESERVOIR SOURING AND CORROSION BY TREATMENT WITH VIRULENT BACTERIOPHAGE | February 2012 | September 2013 | Allow | 19 | 3 | 1 | Yes | No |
| 13308809 | SWINE INFLUENZA HEMAGGLUTININ VARIANTS | December 2011 | December 2013 | Allow | 24 | 2 | 1 | No | No |
| 13265024 | TAG PEPTIDE HAVING A PROTEASE RECOGNITION SEQUENCE AND USE THEREOF | November 2011 | December 2012 | Allow | 14 | 1 | 1 | No | No |
| 13258867 | POLYION COMPLEX COMPRISING HYDROPHOBIZED POLYAMINO ACID AND USE OF THE SAME | November 2011 | July 2014 | Allow | 34 | 1 | 0 | No | No |
| 13277989 | SENSORS FOR DETECTING SUBSTANCES INDICATIVE OF STROKE, ISCHEMIA, INFECTION OR INFLAMMATION | October 2011 | December 2011 | Allow | 2 | 0 | 0 | No | No |
| 13271451 | IMPLANTS AND METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE | October 2011 | March 2012 | Allow | 6 | 1 | 0 | No | No |
| 13267870 | COMPOSITIONS AND METHODS FOR ATTRACTING NOCTUID MOTHS | October 2011 | April 2013 | Allow | 19 | 2 | 2 | No | No |
| 13230479 | WOUND CARE DEVICE | September 2011 | December 2012 | Allow | 15 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FOLEY, SHANON A.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 80.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner FOLEY, SHANON A works in Art Unit 1671 and has examined 175 patent applications in our dataset. With an allowance rate of 91.4%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner FOLEY, SHANON A's allowance rate of 91.4% places them in the 75% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by FOLEY, SHANON A receive 1.70 office actions before reaching final disposition. This places the examiner in the 48% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by FOLEY, SHANON A is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +3.8% benefit to allowance rate for applications examined by FOLEY, SHANON A. This interview benefit is in the 25% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 37.2% of applications are subsequently allowed. This success rate is in the 82% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 68.0% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 90.9% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 70.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 44.9% are granted (fully or in part). This grant rate is in the 49% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 1.7% of allowed cases (in the 75% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.5% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.